The D3 research ‘follows the drug’ across episodes of digitalization. Through this, the medicine as a material object is placed at the centre of the investigation – as the ‘thing’ (the drug, the tablet, the therapy), and as digital traces (representations), or as combined in some new hybrid digital materiality or assemblage.

As we followed the drug, we mapped the ways it enters into use, and moves from use in the supply chain, to clinical use, to use for research, management and commissioning purposes…

A first map* of these movements and places was shared and discussed at the workshop.

And everyone was invited to comment, fill the gaps and suggest possible alternative maps…

…with more details of the different information systems along the way…

…the infrastructures, and interconnections …

… the value of data, and of the evidence of effectiveness…

…or with greater focus on the patient’s views…

*Note: This map is a ‘research process’. In many ways, this is possibly a ‘wrong map’. But when maps appear to be wrong, they are more generative of ideas and open up discussions…